A new treatment was approved in Japan in 2020 called nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/levo-leucovorin (Levo-LV). One drawback was that this regimen required a long administration time because the Levo-LV had to be given separately after the nal-IRI.

Since this was causing a burden on both patients and the outpatient chemotherapy room, the hospital decided to try a new approach called parallel administration. This means that they started giving the nal-IRI and Levo-LV at the same time. The hospital reviewed the data of 69 patients who received this treatment between June 2020 and October 2021 to see if the parallel method was safe and effective.

They found that there were no problems with giving the drugs simultaneously, and there were no major differences in how well the treatment worked or in the side effects compared to the conventional method. However, the parallel method did have a significant advantage in that it reduced the administration time, making it more convenient for patients and healthcare workers.

So, the conclusion of the study is that the parallel administration of nal-IRI and Levo-LV is a safe and effective method for treating pancreatic cancer. It also saves time, which is a big advantage for everyone involved.